All In Biotech

Drug Trial Radar · NCT07839000

A Clinical Trial to Evaluate [14C]-MK-4208/[14C]-TERN-701 in Healthy Adult Male Participants (MK-4208-002/TERN701-1016)

A Phase 1, Open-Label, Mass Balance Study to Investigate the Absorption, Distribution, Metabolism, and Excretion of 14C-TERN-701 Following Administration of a Single Oral Dose in Healthy Adult Male Participants

Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

8

Actual

Start

Feb 25, 2026

Primary completion

Apr 3, 2026

Study completion Apr 3, 2026

Sponsor

Sponsor type
Industry
First posted
Sep 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of the study is to learn what happens to different forms of TERN-701 medications in a healthy person's body over time. Researchers will compare what happens to different forms of TERN-701 in a person's body over time. The goal of the study is to learn: * What happens to different forms of TERN-701 in a person's body over time. * The amount and number of different forms of TERN-701 that leave a person's body over time.

Conditions

  • Healthy

Interventions

  • TERN-701Drug

    Oral Liquid radiolabeled with \[14C\]-TERN-701

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Total Amount of [14C]-Radiolabel Excreted into Urine per Sampling Interval (Aeurine,14C,t1-t2)Time frame: Pre-dose and at designated time points up to 408 hours post dose
  2. Cumulative Percentage of Total Amount of [14C]-Radiolabel Excreted into Urine up to the Last Sampling Interval (Aeurine,14C)Time frame: Pre-dose and at designated time points up to 408 hours post dose
  3. Percentage of Total Amount of [14C]-Radiolabel Excreted into Feces per Sampling Interval (Aefeces,14C,t1-t2)Time frame: Pre-dose and at designated time points up to 408 hours post dose
  4. Cumulative Percentage of Total Amount of [14C]-Radiolabel Excreted into Feces Up to the Last Sampling Interval (Aefeces,14C)Time frame: Pre-dose and at designated time points up to 408 hours post dose
  5. Percentage of Total Amount of [14C]-Radiolabel Excreted from Body per Sampling Interval (Aetotal, 14C, t1-t2)Time frame: Pre-dose and at designated time points up to 408 hours post dose
  6. Cumulative Percentage of Total Excretion of [14C]-Radiolabel from the Body (Aetotal, 14C)Time frame: Pre-dose and at designated time points up to 408 hours post dose
  7. Maximum Concentration Observed in Plasma (Cmax) of TERN-701 in PlasmaTime frame: Pre-dose and at designated time points up to 408 hours post dose
  8. Time to Maximum Concentration Observed in Plasma (Tmax) of TERN-701 in PlasmaTime frame: Pre-dose and at designated time points up to 408 hours post dose
  9. Apparent Terminal Half-Life (t1/2) of TERN-701 in PlasmaTime frame: Pre-dose and at designated time points up to 408 hours post dose
  10. Area Under the Concentration-Time Curve from Time 0 to the Last Quantifiable Concentration (AUC0-last) of TERN-701 in PlasmaTime frame: Pre-dose and at designated time points up to 408 hours post dose
  11. Area Under the Concentration-Time Curve from Time 0 Extrapolated to Infinity (AUC0-Inf) of TERN-701 in PlasmaTime frame: Pre-dose and at designated time points up to 408 hours post dose
  12. Apparent Oral Clearance (CL/F) of TERN-701 in PlasmaTime frame: Pre-dose and at designated time points up to 408 hours post dose
  13. Apparent Volume of Distribution (Vz/F) of TERN-701 in PlasmaTime frame: Pre-dose and at designated time points up to 408 hours post dose
  14. Total [14C]-Radiolabel in PlasmaTime frame: Pre-dose and at designated time points up to 408 hours post dose
  15. Tmax of Total [14C]-Radiolabel in PlasmaTime frame: Pre-dose and at designated time points up to 408 hours post dose
  16. t1/2 of Total [14C]-Radiolabel in PlasmaTime frame: Pre-dose and at designated time points up to 408 hours post dose
  17. AUC0-last of Total [14C]-Radiolabel in PlasmaTime frame: Pre-dose and at designated time points up to 408 hours post dose
  18. AUC0-Inf of Total [14C]-Radiolabel in PlasmaTime frame: Pre-dose and at designated time points up to 408 hours post dose
  19. Cmax of Total [14C]-Radiolabel in PlasmaTime frame: Pre-dose and at designated time points up to 408 hours post dose
  20. Tmax of Total [14C]-Radiolabel in Whole BloodTime frame: Pre-dose and at designated time points up to 408 hours post dose
  21. t1/2 of Total [14C]-Radiolabel in Whole BloodTime frame: Pre-dose and at designated time points up to 408 hours post dose
  22. AUC0-last of Total [14C]-Radiolabel in Whole BloodTime frame: Pre-dose and at designated time points up to 408 hours post dose
  23. AUC0-Inf of Total [14C]-Radiolabel in Whole BloodTime frame: Pre-dose and at designated time points up to 408 hours post dose
  24. Cmax of Total [14C]-Radiolabel in Whole BloodTime frame: Pre-dose and at designated time points up to 408 hours post dose
  25. Cumulative Amount of Total [14C]-Radiolabel Excreted in Urine (Aeurine)Time frame: Pre-dose and at designated time points up to 408 hours post dose
  26. Renal Clearence (CLr) of [14C] radioactivityTime frame: Pre-dose and at designated time points up to 408 hours post dose
  27. Percent of Dose Excreted as Radioactivity in Urine (%Feurine) of [14C] radioactivityTime frame: Pre-dose and at designated time points up to 408 hours post dose
  28. Cumulative Amount of Total [14C]-Radiolabel Excreted in Feces (Aefeces) of [14C] radioactivityTime frame: Pre-dose and at designated time points up to 408 hours post dose
  29. Percent of Dose Excreted as Radioactivity in Feces (%Fefeces) of [14C] radioactivityTime frame: Pre-dose and at designated time points up to 408 hours post dose
  30. Percentage Area Under the Concentration-Time Curve (AUC) of [14C]-Radiolabel TERN-701 Metabolite in PlasmaTime frame: Pre-dose and at designated time points up to 408 hours post dose
  31. Percentage of Administered Dose of [14C]-Radiolabel TERN-701 Metabolite in FecesTime frame: Pre-dose and at designated time points up to 408 hours post dose
  32. Percentage of the [14C]-Radiolabel TERN-701 Metabolite in UrineTime frame: Pre-dose and at designated time points up to 408 hours post dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Pharmaron CPC Inc

    Baltimore, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.